46th week of 2013 patent applcation highlights part 41 |
Patent application number | Title | Published |
20130302304 | PHARMACOLOGICAL VITREOLYSIS - A method of treating or preventing a disorder, or a complication of a disorder, of an eye of a subject comprising contacting a vitreous and/or aqueous humor with a composition comprising a truncated form of plasmin comprising a catalytic domain of plasmin (TPCD). TPCDs include, but are not limited to, miniplasmin, microplasmin and derivatives and variants thereof. The methods of the invention can be used to reduce the viscosity of the vitreous, liquefy the vitreous, induce posterior vitreous detachment, reduce hemorrhagic blood from the eye, clear or reduce materials toxic to the eye, clear or reduce intraocular foreign substances from the eye, increase diffusion of a composition administered to an eye, reduce extraretinal neovascularization and any combinations thereof. The method can be used in the absence of, or as an adjunct to, vitrectomy. | 2013-11-14 |
20130302305 | Methods for Treating Gout in Patients Subpopulations - The present application discloses a method of lowering serum uric acid level in a subject with impaired renal function, comprising administering to the subject a compound of Formula (I), as disclosed herein. | 2013-11-14 |
20130302306 | BACTERIOPHAGE LYSIN AND ANTIBIOTIC COMBINATIONS AGAINST GRAM POSITIVE BACTERIA - The present invention provides compositions and methods for prevention, amelioration and treatment of gram positive bacteria, particularly Staphylococcal bacteria, with combinations of lysin, particularly Streptococcal lysin, particularly the lysin PlySs2, and one or more antibiotic, including daptomycin, vancomycin, oxacillin, linezolid, or related antibiotic(s). | 2013-11-14 |
20130302307 | Novel Cellular-Factor Containing Solution Compositions - The invention is directed to novel cellular factor-containing solution compositions (referred to herein as “CFS” compositions), including novel sustained-release cellular factor-containing solution compositions (referred to herein as “SR-CFS” compositions), methods of making such novel compositions and uses thereof. | 2013-11-14 |
20130302308 | THERAPEUTIC STRATEGIES TO TREAT CNS PATHOLOGY IN MUCOPOLYSACCHARIDOSES - The invention refers to nucleotide sequence encoding for a chimeric sulfatase, viral vectors expressing such sequences for gene therapy and pharmaceutical uses of the chimeric expressed protein. The invention is particularly applied in the therapy of mucopolysaccharidosis, preferably type IIIA. | 2013-11-14 |
20130302309 | Non-animal soft capsule shell composition having improved disintegration and shell hardness - The present invention relates to a non-animal soft capsule shell composition having improved disintegration stability and shell hardness. More particularly, the present invention relates to a non-animal soft capsule shell composition and to a method for preparing same, in which an antioxidant and a disintegration aid are added to the non-animal soft capsule shell composition that is typically made of starch or a starch derivative, gums, a plasticizer, a buffering agent, and purified water which inhibit starch retrogradation and thus inhibit an increase in disintegration stability and capsule shell hardness, thereby improving disintegration stability and shell hardness. | 2013-11-14 |
20130302310 | Pharmaceutical Composition for Relieving Fatigue and Preparation Method Thereof - Pharmaceutical composition for relieving fatigue and preparation method thereof. A pharmaceutical composition for relieving fatigue and preparation method thereof are provided. The pharmaceutical composition is prepared by mixing ethanol extract of ginseng, ethanol extract of | 2013-11-14 |
20130302311 | EMERGENCY INTERVENTIONS OF ACTIVE CHARCOAL WITH DABIGATRAN ETEXILATE OVERDOSING - The invention relates to a method for treating an overdosing with active substance dabigatran etexilate of formula I | 2013-11-14 |
20130302312 | METHOD OF TREATING A PATHOLOGICAL SYNDROME AND A PHARMACEUTICAL AGENT - A method of treating a pathological syndrome includes administration of an activated form of ultra-low doses of antibodies to an antigen, wherein said activated form is obtained by repeated consecutive dilution combined with external impact, and the antigen is a substance or a pharmaceutical agent exerting influence upon the mechanisms of formation of this particular pathological syndrome. | 2013-11-14 |
20130302313 | HEXON TAT-PTD MODIFIED ADENOVIRUS AND USES THEREOF - The invention provides a hexon Tat-PTD modified adenovirus, a gene delivery vector based on the modified adenovirus that enhances gene delivery efficiency, and an oncolytic agent based on the modified adenovirus that enhances tumor cell killing efficiency and improves therapeutic outcome. | 2013-11-14 |
20130302314 | ANTI-C EPSILON MX ANTIBODIES CAPABLE OF BINDING TO HUMAN MIGE ON B LYMPHOCYTES - The invention pertains to the generation and utility of antibodies that can bind effectively to CεmX domain on membrane-bound IgE (mIgE) expressed on the surface of human B lymphocytes. The CεmX domain of 52 amino acid residues, located between the CH4 domain and the C-terminal membrane-anchor peptide on human membrane-bound epsilon chain, had been suggested as an antigenic site for immunological targeting of B cells expressing mIgE. Previous reported monoclonal antibodies, including a20, which bind to RADWPGPP (SEQ ID NO:1) peptide at the C-terminal of CεmX, have now been found to bind poorly to mIgE on human B cells. We have discovered that only monoclonal antibodies specific for certain segments, such as GLAGGSAQSQRAPDRVL (SEQ ID NO:2) and HSGQQQGLPRAAGGSVPHPR (SEQ ID NO:3), of CεmX can bind effectively to mIgE on human B cells and hence have the utility for targeting those B cells for the treatment of diseases mediated by IgE. | 2013-11-14 |
20130302315 | Optimized Fc Variants - The present invention relates to Fc variants having decreased affinity for FcγRIIb, methods for their generation, Fc polypeptides comprising optimized Fc variants, and methods for using optimized Fc variants. | 2013-11-14 |
20130302316 | ANTAGONIST ANTIBODY FOR THE TREATMENT OF CANCER - Antibodies, humanized antibodies, resurfaced antibodies, antibody fragments, derivatized antibodies, and conjugates of same with cytotoxic agents, which specifically bind to, and inhibit A class of Eph receptors, antagonize the effects of growth factors on the growth and survival of tumor cells, and which have minimal agonistic activity or are preferentially devoid of agonist activity. Said antibodies and fragments thereof may be used in the treatment of tumors that express elevated levels of A class of Eph receptors, such as breast cancer, colon cancer, lung cancer, ovarian carcinoma, synovial sarcoma and pancreatic cancer, and said derivatized antibodies may be used in the diagnosis and imaging of tumors that express elevated levels of A class of Eph receptors. Also provided are cytotoxic conjugates comprising a cell binding agent and a cytotoxic agent, therapeutic compositions comprising the conjugate, methods for using the conjugates in the inhibition of cell growth and the treatment of disease, and a kit comprising the cytotoxic conjugate are disclosed are all embodiments of the invention. In particular, the cell binding agent is a monoclonal antibody, and epitope-binding fragments thereof, that recognizes and binds the A class of Eph receptors. | 2013-11-14 |
20130302317 | Siglec-9 Binding Agents - The present invention relates to agents capable of binding sialic acid-binding immunoglobulin-like lectin-9 (Siglec-9) and their use in the treatment of cell proliferation and differentiation disorders. Furthermore, the present invention provides associated pharmaceutical formulations and methods. | 2013-11-14 |
20130302318 | Anti-CD38 Antibody and Lenalidomide or Bortezomib for the Treatment of Multipe Myeloma and NHL - The present disclosure describes a pharmaceutical combination of an anti-CD38 antibody and lenalidomide and a pharmaceutical combination of an anti-CD38 antibody and bortezomib. | 2013-11-14 |
20130302319 | ZEAXANTHIN FOR TUMOR TREATMENT - A composition comprising a pharmaceutically effective amount of zeaxanthin or its derivative for use in treating a malignant tumor and a method of using a pharmaceutically effective amount of zeaxanthin or its derivative either alone or together with one or more pharmaceutical agents for treating a malignant tumor. The tumor may be, but is not limited to breast cancer, cervix cancer, colon cancer, cutaneous melanoma, cutaneous squamous carcinoma, hepatocellular carcinoma, lung cancer, osteosarcoma, prostate cancer, and uveal melanoma. The pharmaceutically effective amount of zeaxanthin is generally above about 0.5 mg/kg/d to about 20 mg/kg/d. | 2013-11-14 |
20130302320 | Use of Semaphorin-4D Binding Molecules to Promote Neurogenesis Following Stroke - Provided herein are methods for promoting neurogenesis in neural tissue of a patient exhibiting at least one symptom of a central nervous system disorder, the method comprising administering to a subject in need thereof an effective amount of an isolated binding molecule which specifically binds to semaphorin-4D (SEMA4D). | 2013-11-14 |
20130302321 | Methods and Means for Typing a Sample Comprising Cancer Cells Based on Oncogenic Signal Transduction Pathways - The invention is related to a method of determining whether an individual suffering from cancer is likely to respond to anti-EGFR and/or EGFR pathway therapy. In one aspect, the invention utilizes the expression level of a set of genes for determining said response. In a further aspect, the invention relates to a method of assigning treatment to an individual suffering from cancer. | 2013-11-14 |
20130302322 | METHODS OF TREATING CONDITIONS WITH ANTIBODIES THAT BIND COLONY STIMULATING FACTOR 1 RECEPTOR (CSF1R) - Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (CSF1R) are provided. Such methods include, but are not limited to, methods of treating rheumatoid arthritis and associated conditions, methods of treating systemic lupus erythematosus and associated conditions, and methods of treating multiple sclerosis. | 2013-11-14 |
20130302323 | METHODS FOR TREATING DIFFUSE LARGE B-CELL LYMPHOMA WITH 3-(4-AMINO-1-OXO-1,3-DIHYDROISOINDOL-2-YL)-PIPERIDINE-2,6-DIONE IN COMBINATION WITH SECOND ACTIVE AGENTS - Methods of treating, preventing and/or managing cancer as well as and diseases and disorders associated with, or characterized by, undesired angiogenesis are disclosed. Specific methods encompass the administration of an immunomodulatory compound alone or in combination with a second active ingredient. The invention further relates to methods of reducing or avoiding adverse side effects associated with chemotherapy, radiation therapy, hormonal therapy, biological therapy or immunotherapy which comprise the administration of an immunomodulatory compound. Pharmaceutical compositions, single unit dosage forms, and kits suitable for use in methods of the invention are also disclosed. | 2013-11-14 |
20130302324 | Methods for treating retinopathy with extended therapeutic effect - Methods for treating and preventing retinopathic conditions by administering a glucocorticoid to the vitreous chamber of a patient at risk of, or suffering from, the retinopathy. | 2013-11-14 |
20130302325 | METHODS FOR TREATING OSTEOARTHRITIS PAIN BY ADMINISTERING A NERVE GROWTH FACTOR ANTAGONIST AND COMPOSITIONS CONTAINING THE SAME - The invention concerns anti-NGF antibodies (such as anti-NGF antagonist antibodies), and polynucleotides encoding the same. The invention further concerns use of such antibodies and/or polynucleotides in the treatment and/or prevention of pain, including post-surgical pain, rheumatoid arthritis pain, and osteoarthritis pain. | 2013-11-14 |
20130302326 | PYRO-GLUTAMATE ABETA TARGETING AGENTS - A method of inhibiting amyloid beta aggregation in a mammal includes administering an amount of a pyro-Glu-(3-40/42)-Aβ targeting agent and/or fragment thereof that specifically binds to an epitope of the N terminus end of a pyro-Glu-(3-40/42)-Aβ effective to inhibit amyloid beta aggregation in the subject. | 2013-11-14 |
20130302327 | MARKER FOR DETERMINATION OF SENSITIVITY TO TRIPLET COMBINATION ANTI-CANCER AGENT - To provide a marker for determining sensitivity of a patient to an anti-cancer agent, which marker can determine whether or not the patient has a therapeutic response to the anti-cancer agent, and novel cancer therapeutic means employing the marker. | 2013-11-14 |
20130302328 | TRUNCATED HER2 SRM/MRM ASSAY - This disclosure provides ten (10) specific peptides, and particular peptide characteristics, from the cell membrane-bound Her2 protein and a diagnostic assay useful for determining the presence and amount of full length and truncated versions of the full-length Her2 protein in cells derived from formalin fixed paraffin embedded tissue. | 2013-11-14 |
20130302329 | DIAGNOSTIC TESTS FOR IMMUNE REACTIVITY WITH HUMAN ENDOTHELIAL CELL GROWTH FACTOR - The present invention provides for methods and compositions for identifying and detecting autoantigens. Candidate autoantigens are identified by obtaining a subject sample from which HLA-DR-presented peptides are collected and identified using mass spectometry, then synthesized and reacted with the same subject peripheral blood or effected tissue. In particular, the present invention provides for endothelial cell growth factor as a novel autoantigen biomarker for Lyme disease-associated arthritis. | 2013-11-14 |
20130302330 | CHIMERIC ANTIGENS FOR ELICITING AN IMMUNE RESPONSE - Disclosed herein are compositions and methods for eliciting immune responses against antigens. In particular embodiments, the compounds and methods elicit immune responses against antigens that are otherwise recognized by the host as “self” antigens. The immune response is enhanced by presenting the host immune system with a chimeric antigen comprising an immune response domain and a target binding domain, wherein the target binding domain comprises a xenotypic antibody fragment. By virtue of the target binding domain, antigen presenting cells take up, process, and present the chimeric antigen, eliciting both a humoral and cellular immune response. | 2013-11-14 |
20130302331 | METHOD OF DELIVERING RNA INTERFERENCE AND USES THEREOF - The invention provides a method of RNA interference, which comprises contacting the cell with a fusion protein-double stranded RNA complex, the complex comprising the double stranded RNA segment containing a double stranded RNA of interest and a fusion protein, the fusion protein comprising (1) a targeting moiety, which will specifically binds to a site on a target cell, and (2) a binding moiety, which will bind to the double stranded RNA, wherein the double stranded RNA segment initiates RNA interference in the cell. | 2013-11-14 |
20130302332 | METHOD FOR TREATING INFLAMMATION - A method for treating IL-20 induced inflammation. An antagonist to IL-20 is administered to treat inflammation and associated diseases. The antagonist can be an antibody that binds to IL-20 or its receptor or a soluble receptor that binds to IL-20. Examples of such diseases are adult respiratory disease, psoriasis, eczema, contact dermatitis, atopic dermatitis, septic shock, multiple organ failure, inflammatory lung injury, bacterial pneumonia, inflammatory bowel disease, rheumatoid arthritis, asthma, ulcerative colitis and Crohn's disease. | 2013-11-14 |
20130302333 | PREVENTION AND TREATMENT OF COMPLEMENT-ASSOCIATED EYE CONDITIONS - The invention concerns the prevention and treatment of complement-associated eye conditions, such as choroidal neovascularization (CNV) and age-related macular degeneration (AMD), by administration of Factor D antagonists. | 2013-11-14 |
20130302334 | BCL-2-LIKE PROTEIN 11 SRM/MRM ASSAY - Specific peptides, and derived ionization characteristics of those peptides, from the Bcl-2-like protein 11 (BIM) are provided that are particularly advantageous for quantifying the BIM protein directly in biological samples that have been fixed in formalin by the method of Selected Reaction Monitoring (SRM) mass spectrometry, or what can also be termed as Multiple Reaction Monitoring (MRM). Such biological samples are chemically preserved and fixed where the biological sample is selected from tissues and cells treated with formaldehyde containing agents/fixatives including formalin-fixed tissue/cells, formalin-fixed/paraffin embedded (FFPE) tissue/cells, FFPE tissue blocks and cells from those blocks, and tissue culture cells that have been formalin fixed and or paraffin embedded. A protein sample is prepared from the biological sample using the Liquid Tissue™ reagents and protocol, and the BIM protein is quantitated in the Liquid Tissue™ sample by the method of SRM/MRM mass spectrometry by quantitating in the protein sample at least one or more of the peptides described. These peptides can be quantitated if they reside in a modified or an unmodified form. An example of a modified form of a BIM peptide is phosphorylation of a tyrosine, threonine, serine, and/or other amino acid residues within the peptide sequence. | 2013-11-14 |
20130302335 | LIGANDS THAT BIND TGF-BETA RECEPTOR II - The disclosure provides an anti-TGFbetaRII immunoglobulin single variable domain. Suitably, an anti-TGFbetaRII immunoglobulin single variable domain in accordance with the disclosure is one having an amino acid sequence as set forth in any one of SEQ ID NO:1-28 having up to 5 amino acid substitutions, deletions or additions. The disclosure further provides a polypeptide and pharmaceutical composition for treating a disease associated with TGFbeta signalling and suitably a disease selected from the group of: tissue fibrosis, such as pulmonary fibrosis, including idiopathic pulmonary fibrosis; liver fibrosis, including cirrhosis and chronic hepatitis; rheumatoid arthritis; ocular disorders; fibrosis of the skin, including keloid of skin; Dupuytren's Contracture; kidney fibrosis such as nephritis and nephrosclerosis; wound healing; scarring reduction; and a vascular condition, such as restenosis. | 2013-11-14 |
20130302336 | DISULFIDE STABILIZED DVD-IG MOLECULES - A re-epoxidized polyfunctional epoxy resin composition comprising the reaction product of: (I) an epoxidized polyfunctional epoxy resin oligomeric composition comprising a polyfunctional aliphatic or cycloaliphatic epoxy resin which has been isolated from an epoxy resin product formed as a result of an epoxidation process comprising the reaction of: (i) an aliphatic or cycloaliphatic hydroxyl-containing material; (ii) an epihalohydrin, (iii) a basic-acting substance, in the presence of (iv) a non-Lewis acid catalyst; and (v) optionally, one or more solvents; (II) an epihalohydrin; (III) a basic acting substance; in the presence of (IV) a non-Lewis acid catalyst; and (V) optionally, one or more solvents. A curable epoxy resin composition of the re-epoxidized polyfunctional epoxy resin composition and a thermoset of the curable composition is also disclosed. | 2013-11-14 |
20130302337 | METHODS AND COMPOSITIONS FOR TREATING ALZHEIMER'S DISEASE - This disclosure relates to methods and compositions useful for treating Alzheimer's disease. In particular, the disclosure relates to pharmaceutical compositions containing an EGFR-inhibitory compound suitable for administration to treat Alzheimer's disease, as well as to related therapeutic methods. In addition, this disclosure relates to screening methods for identifying compounds useful for treating Alzheimer's disease based on the ability to inhibit the activity of EGFR. | 2013-11-14 |
20130302338 | DERMATOPHAGOID PTERONYSSINUS (DER P1) ANTIGEN EPITOPE AND ANTI-DER P1 ANTIBODY - The present invention provides a novel isolated peptide segment which is a | 2013-11-14 |
20130302339 | COMPOSITIONS FOR DIAGNOSIS AND THERAPY OF DISEASES ASSOCIATED WITH ABERRANT EXPRESSION OF KREMEN AND OR WNT - The present invention relates to a composition useful for the diagnosis and therapy of diseases associated with aberrant expression of the gene encoding the receptor Kremen 1 and/or Kremen 2 e.g. tumors or diseases of the kidneys, bones and eyes, lipid and glucose metabolism and obesity. The present invention also relates to a pharmaceutical composition containing a compound which is capable of modifying (a) the expression of the gene encoding Kremen 1 and/or Kremen 2 or (b) the activity of the Kremen 1 and/or Kremen 2 receptor. | 2013-11-14 |
20130302340 | HUMAN TIMP-1 ANTIBODIES - Human antibodies that bind to TIMP-1 can be used as reagents to diagnose and treat disorders in which TIMP-1 is elevated, such as liver fibrosis, alcoholic liver disease, cardiac fibrosis, acute coronary syndrome, lupus nephritis, glomerulosclerotic renal disease, benign prostate hypertrophy, colon cancer, lung cancer, and idiopathic pulmonary fibrosis. | 2013-11-14 |
20130302341 | THERAPEUTIC AND DIAGNOSTIC APPLICATIONS TARGETING TNK-1 - Disclosed herein are novel antibodies specific to Tnk1 or variants thereof. Also disclosed are methods of using such antibodies. The methods include therapeutic methods against certain types of cancers or infections involving administration of novel antibodies or fragments thereof. Also, methods of using highly selective antibodies for detecting aberrant Tnk1 or functionally deficient Tnk1. | 2013-11-14 |
20130302342 | HUMAN LACTOFERRIN DERIVED PEPTIDE FOR USE AS AN ANTIGEN MASKING AGENT - The invention refers to a human lactoferrin derived peptide for use as an antigen masking agent in the production of a pharmaceutical composition for delivery of a biological active substance in a mammalian organism, where the biological active substance is able to induce an undesired immune response by the mammalian organism, where the pharmaceutical composition comprises a supramolecular aggregate of the biological active substance and the human lactoferrin derived peptide, with the effect that after delivery of pharmaceutical composition to the mammalian organism, there is no or only a diminished induction of the undesired immune response against the biological active substance. | 2013-11-14 |
20130302343 | MODULATORS OF IL-12 AND/OR IL-23 FOR THE PREVENTION OR TREATMENT OF ALZHEIMER'S DISEASE - The invention provides antibody against p40, IL-12 or IL-23 for the prevention or treatment of Alzheimer's disease. It further provides ligands to the pair of interleukin 12 or 23 and its specific receptor, specifically an antibody, an antibody fragment, an antibody-like-molecule, for the prevention or treatment of Alzheimer's disease. Similarly, siRNA, antisense or transcription factor modulators of gene expression of p19, p35, p40, IL-12R-β1, IL-12R-β2, and/or IL-23R for the prevention or treatment of Alzheimer's disease are provided. | 2013-11-14 |
20130302344 | METHODS AND MEDICAMENTS FOR THE TREATMENT OF GOUT OR PSEUDOGOUT - The present invention relates to a new method, and the process to manufacture a medicament, for treating gout or pseudogout, comprising administering an effective amount of inhibitors blocking IL-1 or its maturation by the NALP3 inflammasome. | 2013-11-14 |
20130302345 | CD89 ACTIVATION IN THERAPY - The invention relates to the use of CD89 activating molecules, in particular Fc alpha comprising molecules, and more particularly, IgA, for inducing apoptosis in neutrophils. Anti-CD89 antibodies can alternatively be used. The CD89 activation is beneficial in the treatment of various disorders associated with increases in neutrophils, such as autoimmune disorders, inflammatory disorders, NETosis, or cystic fibrosis. | 2013-11-14 |
20130302346 | ANTIBODIES THAT BIND NOTUM PECTINACETYLESTERASE - Antibodies that neutralize Notum Pectinacetylesterase are described, as well as compositions comprising them, and methods of their use to treat diseases and disorders affecting the bone. | 2013-11-14 |
20130302347 | NOVEL RECEPTOR-LIGAND INTERACTION AND USES THEREOF - Described herein is a novel receptor-ligand interaction and agents that may modify and/or block the interaction. Methods, uses, reagents and kits for the modulation of ligand activities related to its interaction with the novel receptor are disclosed. Also disclosed are therapeutic uses of reagents in treating inflammation-related disorders. | 2013-11-14 |
20130302348 | AGENTS FOR INFLUENZA NEUTRALIZATION - The present invention provides antibodies (e.g., monoclonal antibodies, human antibodies, humanized antibodies, etc.), which bind to multiple influenza strains. Such antibodies are useful, for example, in the prophylaxis, treatment, diagnosis, and/or study of influenza. | 2013-11-14 |
20130302349 | NOVEL HA BINDING AGENTS - This disclosure relates to novel peptide agents, e.g., antibodies and antigen-binding fragments thereof, that bind hemagglutinin protein of influenza viruses, and methods of their use. | 2013-11-14 |
20130302350 | HUMAN CYTOMEGALOVIRUS NEUTRALIZING ANTIBODIES AND USE THEREOF - The invention relates to neutralizing antibodies, and antibody fragments thereof, having high potency in neutralizing hCMV, wherein said antibodies and antibody fragments are specific for one, or a combination of two or more, hCMV gene UL products. The invention also relates to immortalized B cells that produce, and to epitopes that bind to, such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies, antibody fragments, and epitopes in screening methods as well as in the diagnosis, prevention, and therapy of disease. | 2013-11-14 |
20130302351 | ANTAGONISM OF THE VIP SIGNALING PATHWAY - The disclosure relates to inhibition of the VIP signaling pathway. In certain embodiments, the disclosure relates to methods of treating or preventing a viral infection comprising administering a VIP antagonist to a subject in need thereof. | 2013-11-14 |
20130302352 | Methods for the prevention and/or treatment of memory impairment - The present invention relates to methods for the prevention and/or treatment of memory impairment and for improving memory and particularly to methods for the prevention and/or treatment of memory impairment and improving memory comprising administering an agent that decreases activity of a GABA | 2013-11-14 |
20130302353 | ANTIBODIES AGAINST A PROLIFERATING INDUCING LIGAND (APRIL) - The present invention relates to a binding compound which binds to human APRIL. More specifically the invention provides, compositions of anti-APRIL specific antibodies and methods to use such antibodies in modulating the biological activity APRIL, particularly in inflammatory diseases, inhibition of cell proliferation and cancer. | 2013-11-14 |
20130302354 | ALPHA-4-BETA-7 HETERODIMER SPECIFIC ANTAGONIST ANTIBODY - There are disclosed alpha4beta7 heterodimer-specific antigen binding proteins, nucleic acids encoding them, and methods of making and using them. | 2013-11-14 |
20130302355 | NOVEL MODULATORS AND METHODS OF USE - Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat hyper-proliferative disorders are provided. | 2013-11-14 |
20130302356 | Method of Treating Cancer with DLL4 Antagonist and Chemotherapeutic Agent - The invention provides methods for treating various types of cancer/tumor by administering the combination of Dll4 antagonists, in particular, Dll4 antibodies and fragments thereof that specifically bind human Dll4, and chemotherapeutic agents. Such combination therapies exhibit synergistic effects compared to the treatment with either agent alone. Thus, the methods of the invention are particularly beneficial for cancer patients who have low tolerance to the side effects caused by high dosages required for the treatment by either agent alone, by being able to reduce effective dosages. Pharmaceutical compositions and kits containing Dll4 antagonists and chemotherapeutic agents are also provided. | 2013-11-14 |
20130302357 | NOVEL BENZODIAZEPINE DERIVATIVES - The invention relates to novel benzodiazepine derivatives with antiproliferative activity and more specifically to novel benzodiazepines of formula (I) and (II), in which the diazepine ring (B) is fused with a heterocyclic ring (CD), wherein the heterocyclic ring is bicyclic or a compound of formula (III), in which the diazepine ring (B) is fused with a heterocyclic ring (C), wherein the heterocyclic ring is monocyclic. The invention provides cytotoxic dimers of these compounds. The invention also provides conjugates of the monomers and the dimers. The invention further provides compositions and methods useful for inhibiting abnormal cell growth or treating a proliferative disorder in a mammal using the compounds or conjugates of the invention. The invention further relates to methods of using the compounds or conjugates for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions. | 2013-11-14 |
20130302358 | MORPHOLOGICALLY AND SIZE UNIFORM MONODISPERSE PARTICLES AND THEIR SHAPE-DIRECTED SELF-ASSEMBLY - Monodisperse particles having: a single pure crystalline phase of a rare earth-containing lattice, a uniform three-dimensional size, and a uniform polyhedral morphology are disclosed. Due to their uniform size and shape, the monodisperse particles self assemble into superlattices. The particles may be luminescent particles such as down-converting phosphor particles and up-converting phosphors. The monodisperse particles of the invention have a rare earth-containing lattice which in one embodiment may be an yttrium-containing lattice or in another may be a lanthanide-containing lattice. The monodisperse particles may have different optical properties based on their composition, their size, and/or their morphology (or shape). Also disclosed is a combination of at least two types of monodisperse particles, where each type is a plurality of monodisperse particles having a single pure crystalline phase of a rare earth-containing lattice, a uniform three-dimensional size, and a uniform polyhedral morphology; and where the types of monodisperse particles differ from one another by composition, by size, or by morphology. In a preferred embodiment, the types of monodisperse particles have the same composition but different morphologies. Methods of making and methods of using the monodisperse particles are disclosed. | 2013-11-14 |
20130302359 | CYTOTOXIC BENZODIAZEPINE DERIVATIVES - The invention relates to novel benzodiazepine derivatives with antiproliferative activity and more specifically to novel benzodiazepine compounds of formula (I)-(VII). The invention also provides conjugates of the benzodiazepine compounds linked to a cell-binding agent. The invention further provides compositions and methods useful for inhibiting abnormal cell growth or treating a proliferative disorder in a mammal using the compounds or conjugates of the invention. | 2013-11-14 |
20130302360 | MUCOSAL ADJUVANT COMPOSITION - Problem to be Solved: The present invention provides a novel mucosal adjuvant. | 2013-11-14 |
20130302361 | CONSENSUS PROSTATE ANTIGENS, NUCLEIC ACID MOLECULE ENCODING THE SAME AND VACCINE AND USES COMPRISING THE SAME - Provided herein are consensus amino acid sequences of prostate antigens that are capable of breaking tolerance in a targeted species, including PSA, PSMA, STEAP and PSCA antigens. Also provided are nucleic acid sequences that encode one or more consensus amino acid sequences of prostate antigens PSA, PSMA, STEAP and PSCA, as well genetic constructs/vectors and vaccines expressing the sequences. Also provided herein are methods for generating an autoimmune response against prostate cancer cells by administering one or more of the vaccines, proteins, and/or nucleic acid sequences that are provided. | 2013-11-14 |
20130302362 | Immunomodulatory Compositions, Methods and Systems Comprising Immunogenic Fragments of ApoB-100 - Immunostimulatory agents, T cell, compositions, methods and systems for treating and/or preventing various conditions in a human individual. | 2013-11-14 |
20130302363 | DETECTION OF MAGE-A EXPRESSION - An oligonucleotide, primer or probe comprises the nucleotide sequences of any of SEQ ID NO. 5, 6, 7, 2, 3, 4, 8, 9, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 25. The oligonucleotides are useful for the detection of the methylation status of a gene, in particular the MAGE-A | 2013-11-14 |
20130302364 | HIGHLY IMMUNOGENIC HIV P24 SEQUENCES - The invention relates to peptides comprising part or all of a conserved element within a Center-of-Tree (COT) sequence derived from a family of polypeptides encoded by naturally occurring variants of HIV. The invention also relates to immunogenic compositions and vaccines comprising said peptides. The invention also relates to methods for the identification of HIV controller patients based on the detection of the T cells of the patient to mount a cytotoxic T cell response against said peptides and to methods for the identification of immunogenic peptides within a family of variant polypeptides. | 2013-11-14 |
20130302365 | EXTRACTION OF OIL-SOLUBLE PIGMENT FROM MICRO-ORGANISMS - A microalgae extract is disclosed consisting of: (A) 40-95 wt. % of a polar phase comprising: (i) 15-75 wt. % water; (ii) 20-80 wt. % of alcohols, acetone and/or combinations thereof; (iii) 0-10 wt. % of sodium chloride; (iv) up to 40 wt. % of other water soluble components; (B) 5-60 wt. % of an apolar phase comprising: (i) 70-99.5 wt. % of triglycerides, diglycerides, monoglycerides, phosphatides, free fatty acids and/or combinations thereof; (ii) 0.05-25 wt. % of oil-soluble pigment; (iii) up to 30 wt. % of other oil soluble components; and (iv) optionally other components in a concentration that does not exceed 9% by weight of the water contained in the extract, wherein the extract contains less than 0.5% by weight of the apolar phase of apolar organic solvent selected from C | 2013-11-14 |
20130302366 | Conformationally Specific Viral Immunogens - The present invention provides methods of making engineered viral proteins and protein complexes that are useful as vaccine immunogens, engineered viral proteins and protein complexes made using such methods, and pharmaceutical compositions comprising such engineered viral proteins and protein complexes. Such engineered viral proteins and protein complexes may comprise one or more cross-links that stabilize the conformation of an antibody epitope, such as a quaternary neutralizing antibody, and may exhibit an enhanced ability to elicit a protective immune response when administered to a subject as a component of a vaccine. | 2013-11-14 |
20130302367 | VIRUS VECTOR FOR PRIME/BOOST VACCINES, WHICH COMPRISES VACCINIA VIRUS VECTOR AND SENDAI VIRUS VECTOR | 2013-11-14 |
20130302368 | Advanced Prime and Boost Vaccine - This invention relates to vaccines and in particular to the combination of non-integrating, replication-incompetent retroviral vectors (NIV) with virus-like particle (VLP) vaccines to induce an immune response in an animal host following administration to the host. This combination results in a novel vaccine strategy for delivering priming and boost doses, wherein an effective amount of an NIV is administered to the host, followed by an effective amount of a VLP. The concept can be broadly applied to infectious disease vaccines and also to cancer vaccines. | 2013-11-14 |
20130302369 | Immunogenic Bordetella Bronchiseptica Compositions - Provided herein are compositions, combinations, and methods comprising | 2013-11-14 |
20130302370 | REDUCTION OF CONCOMITANT INFECTIONS IN PIGS BY THE USE OF PCV2 ANTIGEN - The present invention relates to a method for reducing the percentage of concomitant infections in pigs or a herd of pigs caused by pathogens other than PCV2 comprising the step administering to said pig(s) an effective amount of PCV2 antigen or an immunogenic composition comprising PCV2 antigen. It also refers to a method for improving the resistance of pigs against concomitant infections with pathogens other than PCV2, comprising the step administering to said pig(s) an effective amount of PCV2 antigen or an immunogenic composition comprising PCV2 antigen. | 2013-11-14 |
20130302371 | Immunogenic Respiratory Syncytial Virus Glycoprotein-Containing VLPs and Related Compositions, Constructs, and Therapeutic Methods - The invention provides immunotherapeutic and prophylactic bacteriophage viral-like particle (VLPs) which are useful in the treatment and prevention of Respiratory Syncytial Virus (RSV) infections and related disorders, including bronchiolitis and viral pneumonia. Related compositions (e.g. vaccines), nucleic acid constructs, and therapeutic methods are also provided. VLPs and related compositions of the invention induce high titer antibody responses against RSV. VLPs, VLP-containing compositions, and therapeutic methods of the invention induce an immunogenic response against RSV infection, confer immunity against RSV infection, protect against RSV infection, and reduce the likelihood of infection by RSV infection. | 2013-11-14 |
20130302372 | VACCINE FOR PROTECTION AGAINST LAWSONIA INTRACELLULARIS - The present invention pertains to the use of a non-live carbohydrate containing composition, the carbohydrate being also found in live | 2013-11-14 |
20130302373 | ATTENUATED MYCOPLASMA GALLISEPTICUM STRAINS - The present invention provides live, attenuated | 2013-11-14 |
20130302374 | Methods And Compositions For Dosing Of Allergens - The present invention comprises methods and compositions for immunotherapy. An aspect of the invention comprises administration of one or more allergens in compositions via oral and sublingual routes. Allergen compositions are administered in dosing intervals wherein the increase in the one or more allergens administered to the patient are provided in increasing volumes of a single concentration of at least one allergen. | 2013-11-14 |
20130302375 | MODULATION OF ANTIGEN IMMUNOGENICITY BY ADDITION OF EPITOPES RECOGNIZED BY NKT CELLS - The invention describes a method and compounds for the prevention and treatment of infections with intracellular organisms, the treatment of tumors, and the prevention of infectious and allergic diseases by vaccination. | 2013-11-14 |
20130302376 | Allogeneic Cancer Cell-based Immunotherapy - Cell-based immunotherapy (e.g., immunization or vaccination) may be improved by frequent administration to a human subject of allogeneic cancer cells secreting a modified heat shock protein (e.g., gp96), depletion of B cells in the subject, or both. Antigen (e.g., epitope derived from neoantigen or tumor antigen of allogeneic or syngeneic cancer cells) may induce a specific immune response in the subject. For example, the epitope bound in an immunogenic complex with the secreted heat shock protein may be obtained from allogeneic cancer cells coexpressing both secreted gp96 and antigen, or from syngeneic cancer cells of the subject expressing only antigen. | 2013-11-14 |
20130302377 | STIMULATING IMMUNE RESPONSE - Methods of treatment or prevention of a cancerous or pre-cancerous condition, of slowing or preventing growth of a cancerous condition, of stimulating a cell-mediated immune response, stimulating a Th1 helper T cell response against a pathogen in a mammal and of treating or preventing inflammatory diseases or disorders that involve administration of N-methyl pyrrolidone (NMP) or a physiologically acceptable salt, solvate, tautomer or prodrug thereof are provided. Also provided are formulations of an active agent. | 2013-11-14 |
20130302378 | MATRIX METALLOPROTEINASE INHIBITORS - The present invention relates to β-hydroxy and amino-substituted carboxylic acids, which act as matrix metalloproteinase inhibitors, particularly diastereomerically pure β-hydroxy carboxylic acids, corresponding processes for their synthesis, and pharmaceutical compositions containing the compounds of the present invention. Compounds of the present invention are useful in the treatment of various inflammatory, autoimmune, and allergic diseases, such as methods of treating asthma, rheumatoid arthritis, COPD, rhinitis, osteoarthritis, psoriatic arthritis, psoriasis, pulmonary fibrosis, wound healing disorders, pulmonary inflammation, acute respiratory distress syndrome, perodontitis, multiple sclerosis, gingivitis, atherosclerosis, neointimal proliferation, which leads to restenosis and ischemic heart failure, stroke, renal diseases, tumor metastasis, and other inflammatory disorders characterized by the over-expression and over-activation of a matrix metalloproteinase. | 2013-11-14 |
20130302379 | Method for Preparing Pharmaceutical Composition for Enhancing Immunity and Pharmaceutical Composition Prepared According to the Method - A method for preparing a pharmaceutical composition for enhancing immunity and a pharmaceutical composition prepared according to the method. The method includes steps of: mixing ginseng ethanol extract with fruit and vegetable fermentation conversion solution to obtain a mixture, namely, the pharmaceutical composition for enhancing immunity; wherein the ginseng ethanol extract is prepared by a following step of: reflux extracting ginseng by ethanol aqueous solution for obtaining the extract, namely, the ginseng ethanol extract; the fruit and vegetable fermentation conversion solution is prepared by following steps of: mixing fruit and vegetable, | 2013-11-14 |
20130302380 | AGENT FOR INDUCING INTERFERON PRODUCTION CONTAINING LACTIC ACID BACTERIA - This invention provides an IFN inducer comprising, as an active ingredient, lactic acid bacteria and capable of inducing IFN production, an immunopotentiating agent or prophylactic agent against virus infection comprising such inducer, and a food or drink product comprising such IFN inducer and having IFN-inducing activity, immunopotentiating activity, or prophylactic activity against virus infection. The agent for inducing IFN production comprises, as active ingredients, lactic acid bacteria that can activate plasmacytoid dendritic cells (pDCs) and promote IFN production, such as | 2013-11-14 |
20130302381 | Implantable Medical Devices Including a Water-Insoluble Therapeutic Agent - A medical device includes an implantable structure and a coating layer including a water-insoluble therapeutic agent and one or more additives selected from xylitol, iodine or Ethylenediaminetetraacetic acid (EDTA), and physiologically-acceptable salts thereof. The one or more additives can be present in an amount effective to increase the rate of release of the water-insoluble therapeutic agent from the coating layer. The implantable medical device structure can be an expandable structure such as a balloon or stent. Also described are methods of making and using such implantable medical devices and coating layers. | 2013-11-14 |
20130302382 | Exercise Performance-Increasing Nutritional Supplement and Related Methods and Compositions - The present invention provides a nutritional supplement, comprising L-carnitine and phosphatidylserine; and optionally, further comprises at least one mineral selected from the group consisting of: iron; copper and zinc; and optionally, further comprises ferrous glycinate, copper glycinate and zinc glycinate. | 2013-11-14 |
20130302383 | LIQUID ORAL COMPOSITION OF LANTHANUM SALTS - The present invention relates to liquid oral pharmaceutical compositions of lanthanum and its pharmaceutically acceptable salts thereof. The present invention further relates to preparation of liquid oral pharmaceutical compositions of lanthanum and its salts and also provides use of such compositions in treating hyperphosphatemia in patients. | 2013-11-14 |
20130302384 | MEDICAL DEVICE CONTAINING A CAKE COMPOSITION COMPRISING ARIPIPRAZOLE AS AN ACTIVE INGREDIENT, AND A CAKE COMPOSITION COMPRISING ARIPIPRAZOLE AS AN ACTIVE INGREDIENT - The present invention provides a medical device containing a cake composition comprising aripiprazole as an active ingredient and capable of suppressing agglomeration of aripiprazole in a suspension obtained by resuspending a freeze-dried substance; and a cake composition comprising aripiprazole as an active ingredient. The present invention relates to a medical device containing, in a storage container whose inner wall is treated with silicone, a freeze-dried cake composition comprising separately prepared aripiprazole as an active ingredient, wherein there is a space between the inner wall and the cake composition; and a cake composition comprising aripiprazole as an active ingredient and having a strength of 5 to 100 N. | 2013-11-14 |
20130302385 | COMPOSITIONS CONTAINING A WATER-BASED GEL AND A WATER-IN-OIL EMULSION - The invention relates to a composition, especially a cosmetic composition, containing (a) a water-based gel phase; and (b) a water-in-oil emulsion phase. | 2013-11-14 |
20130302386 | COSMETIC TEXTILE FIBER, METHOD FOR OBTAINING IT AND USE THEREOF - The present invention describes a polyamide textile fiber comprising conjugated nanoparticles homogeneously dispersed in the fiber, selected from polyethylene glycol-conjugated platinum nanoparticles, hyaluronic acid-conjugated gold nanoparticles and mixtures thereof. The invention also describes how to obtain it as well as its use in a cosmetic skin treatment as a system for the release of said conjugated nanoparticles. | 2013-11-14 |
20130302387 | Compositions and Formulations for the Treatment of Halitosis - An orally disintegrating composition comprising a chelate comprising a metal ion and a biologically acceptable amino acid and having the general formula | 2013-11-14 |
20130302388 | Method of Skin Massaging - The present invention is a skin cosmetic comprising agar hydrogel particles having an average particle size of 0.2-5 mm obtained by stirring and cooling, in an oil based solvent, an agar aqueous solution prepared such that the breaking stress after the cooling/solidification is 0.005-0.1 MPa and an oil based gel prepared by mixing fine particles of silicone that are three-dimensionally cross-linked chemically and silicone oil and/or hydrocarbon oil. | 2013-11-14 |
20130302389 | COSMETIC COMPOSITION CONTAINING AT LEAST TWO OSMOLYTES WITH A MOISTURIZING OR ANTIAGING EFFECT - The present invention relates to a cosmetic composition, which comprises a combination of at least two osmolytes chosen from the group comprising taurine or a derivative thereof, inositol, betaine and trehalose. | 2013-11-14 |
20130302390 | INDUCTION OF A PHYSIOLOGICAL DISPERSION RESPONSE IN BACTERIAL CELLS IN A BIOFILM - One aspect of the present invention is directed to a composition. The composition includes a dispersion inducer comprising: | 2013-11-14 |
20130302391 | OIL-IN-WATER EMULSION COMPOSITION AND METHOD FOR PRODUCING THE SAME - Disclosed is an oil-in-water type emulsion composition containing a physiologically acceptable salt of a tranexamate ester and a method for producing the same. An oil-in-water type emulsion composition containing a physiologically acceptable salt of a tranexamate ester can be obtained by preparing an oil phase including: A) a physiologically acceptable salt of a tranexamate ester; B) an amphiphilic substance; C) an oily substance; and D) water, a water-soluble organic solvent or a mixture thereof wherein the weight ratio of the ingredients A:B is in the range of 1:0.5 to 1:2.5, the weight ratio of the ingredients A:C is in the range of 1:1 to 1:5.0, and the weight ratio of the ingredients A:D is 1:0.2 to 1:5.0, and adding the oil phase to a water phase including E) water, a water-soluble organic solvent or a mixture thereof. | 2013-11-14 |
20130302392 | HYDROGEL MICROCAPSULES - The present application provides hydrogel microcapsules, particularly, canonized hydrogel microcapsules having improved substantivity. This application further relates to the use of hydrogel microcapsules for delivering encapsulated actives in a wide range of industries and applications including: agrochemicals, pharmaceuticals, cosmetics industry, personal care products, laundering detergents, homecare & cleaning products, dish washing detergents, oral care, dental care, textiles, paper, mining, oil industry, water treatment, adhesives, coatings, plastics, sealants, construction, paints, inks and dyes onto different substrate surfaces such as skin, hair, textiles. | 2013-11-14 |
20130302393 | ORAL CARE COMPOSITIONS COMPRISING PEARLESCENT PIGMENTS - The invention provides an oral care composition suitable for delivering a temporary whitening effect to the surface of teeth, the composition comprising: a continuous phase comprising water or polyhydric alcohol or a mixture thereof; a tooth surface whitening agent which is dispersed in the continuous phase, and a deposition aid for the tooth surface whitening agent; characterised in that the tooth surface whitening agent is a pearlescent pigment in an amount of at least 0.1% by weight based on the total weight of the composition, the pearlescent pigment being formed by coating one or more metal oxide layers onto particles of an inorganic substrate. | 2013-11-14 |
20130302394 | SOLID ANHYDROUS COSMETIC COMPOSITION - The present invention relates especially to a solid anhydrous cosmetic composition comprising at least: at least 0.1% by weight of hollow particles relative to the total weight of the said composition, said composition being chosen from hydrophobic silica aerogel particles; a volatile oil; at least 5% by weight of at least one organopolysiloxane elastomer; and a wax. | 2013-11-14 |
20130302395 | COATED ANTIMICROBIAL ARTICLES - Antimicrobial articles that include a fatty acid monoester and an enhancer are described that are effective for killing at least 99.9% of microorganisms on the surface of the article. | 2013-11-14 |
20130302396 | Co-Delivery Of Stimulatory And Inhibitory Factors To Create Temporally Stable And Spatially Restricted Zones - The invention provides methods and compositions for local manipulation of regenerative processes via exogenous factor delivery. | 2013-11-14 |
20130302397 | IMPLANTABLE DEVICE FOR THE DELIVERY OF HISTRELIN AND METHODS OF USE THEREOF - This invention is related to the use of polyurethane-based polymer as a drug delivery device to deliver biologically active histrelin at a constant rate for an extended period of time and methods of manufactures thereof. The device is very biocompatible and biostable, and is useful as an implant in patients (humans and animals) for the delivery of histrelin to tissues or organs. | 2013-11-14 |
20130302398 | INTRAOCULAR DRUG DELIVERY DEVICE AND ASSOCIATED METHODS - Devices, systems, and methods for delivery of an active agent into the eye of a subject can include an intraocular active agent delivery device including an active agent dispersed within a biodegradable active agent matrix. The active agent includes dexamethasone and the delivery device is adapted to fit within a lens capsule or ciliary sulcus of an eye. The delivery device can be inserted into the lens capsule or ciliary sulcus of an eye during cataract surgery or for treatment of uveitis. | 2013-11-14 |
20130302399 | ANTI-PCSK9 ANTIBODIES AND USE THEREOF - The present invention is directed to antibodies and fragments thereof having binding specificity for PCSK9. Another embodiment of this invention relates to the antibodies described herein, and binding fragments thereof, comprising the sequences of the V | 2013-11-14 |
20130302400 | Combination therapy with an anti-hyaluronan agent and therapeutic agent - Provided herein is combination therapy containing an anti-hyaluronan agent, such as a polymer-conjugated hyaluronan-degrading enzyme, and a tumor-targeted taxane, and optionally a further chemotherapeutic agent such as a nucleoside analog. The combination therapy can be used in methods of treating cancers, and in particular solid tumor cancers. | 2013-11-14 |
20130302401 | POLY(BETA-AMINO ALCOHOLS), THEIR PREPARATION, AND USES THEREOF - A new class of poly(beta-amino alcohols) (PBAAs) has been prepared using combinatorial polymerization. The inventive PBAAs may be used in biotechnology and biomedical applications as coatings (such as coatings of films or multilayer films for medical devices or implants), additives, materials, excipients, non-biofouling agents, micropatterning agents, and cellular encapsulation agents. When used as surface coatings, these PBAAs elicited different levels of inflammation, both in vitro and in vivo, depending on their chemical structures. The large chemical diversity of this class of materials allowed us to identify polymer coatings that inhibit macrophage activation in vitro. Furthermore, these coatings reduce the recruitment of inflammatory cells, and reduce fibrosis, following the subcutaneous implantation of carboxylated polystyrene microparticles. These polymers may be used to form polyelectrolyte complex capsules for cell encapsulation. The invention may also have many other biological applications such as antimicrobial coatings, DNA or siRNA delivery, and stem cell tissue engineering. | 2013-11-14 |
20130302402 | OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES, THEIR PREPARATION AND USE - This invention provides compounds having the structure | 2013-11-14 |
20130302403 | Vivo Delivery of Double Stranded RNA to an Interleukin-12 Producing Organ or Tissue - The invention encompasses methods of delivering nucleic acids, including dsRNA, to mammalian target cells in vivo via intercellular transfer, wherein the dsRNA is delivered to or expressed in a first cell different from the target cell, wherein the first cell facilitates delivery of the dsRNA to the target cell. | 2013-11-14 |